Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
Business Wire•15/10/2026•12:46 ET
1
Key Highlights
- ➤Signatera named to TIME’s Best Inventions of 2026 Medical & Healthcare category
- ➤Signatera used by more than 55% of U.S. oncologists
- ➤Signatera supported by more than 200 peer-reviewed publications
- ➤Natera named to Fortune’s Future 120 in October 2026
Expert Statements
Steve Chapman, Chief executive officer of Natera
“One of the biggest problems in cancer care is knowing who needs additional therapy and who might safely avoid it”
Steve Chapman, Chief executive officer of Natera
“Signatera can help guide those challenging decisions, because it can detect disease recurrence in the blood up to two years in advance of imaging, giving patients and their doctors greater lead time and confidence. We are honored to receive this important recognition from TIME.”
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
Signatera recognized in the Medical & Healthcare category for its transformative impact on cancer care
Get started
Create a free account to read the full story.